

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/080316 A3

(51) International Patent Classification⁷: **C07C 233/68**,
233/77, 63/04, 69/78, A61K 31/167, 31/192, 31/216,
31/235

(GB). **PRYCE, Gareth** [GB/GB]; Department of Neu-
roinflammation, Institute of Neurology, University College
London, 1 Wakefield Street, London WC1N 1PJ (GB).

(21) International Application Number:
PCT/GB2005/000605

(74) Agents: **CLYDE-WATSON, Zoe** et al.; D Young & Co,
120 Holborn, London EC1N 2DY (GB).

(22) International Filing Date: 21 February 2005 (21.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0403864.2 20 February 2004 (20.02.2004) GB

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(71) Applicant (*for all designated States except US*): **UNIVER-
SITY COLLEGE LONDON** [GB/GB]; Wolfson Institute
for Biomedical Research, The Cruciform Building, Gower
Street, London WC1E 6BT (GB).

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **OKUYAMA,
Masahiro** [JP/JP]; Mitsubishi Pharma Corporation, 6-9,
Hiranomachi, 2 Chome, Chuo-ku, Osaka 541-0046 (JP).
SELWOOD, David [GB/GB]; Wolfson Institute for
Biomedical Research, University College London, The
Cruciform Building, Gower Street, London WC1E 6BT
(GB). **VISINTIN, Cristina** [IT/GB]; Wolfson Institute
for Biomedical Research, University College London,
The Cruciform Building, Gower Street, London WC1E
6BT (GB). **BAKER, David** [GB/GB]; Department of
Neuroinflammation, Institute of Neurology, University
College London, 1 Wakefield Street, London WC1N 1PJ


Published:

— with international search report

(88) Date of publication of the international search report:
3 November 2005

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: MODULATORS OF CANNABINOID RECEPTORS



(I)

(57) Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR¹ or NR¹R² wherein each of R¹ and R² is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO₂-alkyl, alkenyl, CN, NH₂, hydroxy, halo, alkoxy, CF₃ and nitro; Y is a polar functional group selected from OH, NO₂, CN, COR³, COOR³, NR³R⁴, CONR³R⁴, SO₃H, SO₂-R³, SO₂NR³R⁴ and CF₃, where each of R³ and R⁴ is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH₂)_n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X-Y is other than *meta*-C≡C-(CH₂)₂CO₂H, *meta*-C≡C-(CH₂)₂OH, *meta*-C≡C-(CH₂)₂CO₂Me, *meta*-(CH₂)₄CO₂H, *ortho*-CH₂CO₂H, *ortho*-(CH₂)₂CO₂H and *ortho*-(CH₂)₄CO₂H; and (ii) when A is phenyl, n is 0, and Z is OMe, X-Y is other than *meta*-C≡C-(CH₂)₄OH. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors.